James McArthur, PepGen president and CEO (via PepGen)

Pep­Gen de­lays PhI study on my­oton­ic dy­s­tro­phy as it awaits more in­fo on clin­i­cal hold

Pep­Gen is no longer mov­ing ahead with a Phase I study for its can­di­date for my­oton­ic dy­s­tro­phy type 1 (DM1) out­side of the US while …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA